Electronic Supplementary Material: Online Resource 2


International Journal of Clinical Oncology

Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer

Naohiro Nishida, Eisuke Iwasaki, Ken-Ichi Okada

Corresponding author: Naohiro Nishida
Department of Clinical Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
E-mail: nnishida@tokai.ac.jp

Online Resource 2. Genomic alteration profiles and survival analyses according to clinically relevant biomarkers.



(a) Frequency of KRAS mutation detection across each gene panel. Tissue-based panels included NCC Oncopanel, FoundationOne CDx, and GenMineTOP, while liquid biopsy panels included FoundationOne Liquid CDx and Guardant360.

(b) Comparison of mutation detection frequencies for the 30 most frequently altered genes. The x-axis indicates mutation frequencies detected by tissue-based panels, and the y-axis indicates mutatioN frequencies detected by liquid biopsy panels.